A new study shows that blocking the IL-1β signaling pathway in the brain can halt the damaging inflammation that drives neuromyelitis optica (NMO), a severe autoimmune disease. Researchers found that using an antisense oligonucleotide (ASO) to lower IL-1β levels protected nerve cells and improved movement in mice, offering a promising new treatment approach for this condition.

Key Highlights • A new study shows that blocking the IL-1β signaling pathway in the brain can halt the damaging…